A study in scarlet-convalescent plasma for severe influenza

Critical Care Medicine

Volumn 40, Issue 3, 2012, Pages 1027-1028

  Beigel, John H ^a   Luke, Thomas C ^b  

^a SAIC FREDERICK INC   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

convalescent; H1N1; H5N1; influenza; passive immunotherapy; plasma; treatment

Indexed keywords

OSELTAMIVIR;

ANTIVIRAL THERAPY; AVIAN INFLUENZA; BODY WEIGHT; CONVALESCENCE; CONVALESCENT PLASMA; DISEASE SEVERITY; EDITORIAL; HEMAGGLUTINATION INHIBITION; HUMAN; INFLAMMATION; INFLUENZA; INFLUENZA A (H5N1); NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEASONAL INFLUENZA; SURVIVAL RATE; VIRUS REPLICATION; VIRUS SHEDDING; WEIGHT REDUCTION;

ANIMALS; IMMUNE SERA; INFLUENZA A VIRUS, H5N1 SUBTYPE; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84857604503     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31823d77c3     Document Type: Editorial

References (14)

1. McGeer A, Green KA, Plevneshi A, et al: Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568-1575
2. Adisasmito W, Chan PK, Lee N, et al: Effectiveness of antiviral treatment in human influenza A (H5N1) infections: Analysis of a Global Patient Registry. J Infect Dis 2010;202:1154-1160
3. Kumar A, Zarychanski R, Pinto R, et al: Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009;302:1872-1879
4. Skarbinski J, Jain S, Bramley A, et al: Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States-September- October 2009. Clin Infect Dis 2011;52(Suppl 1): S50-S59
5. Bautista E, Chotpitayasunondh T, Gao Z, et al: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-1719
6. Moore C, Galiano M, Lackenby A, et al: Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus in a hematology unit. J Infect Dis 2011;203:18-24
7. Sheu TG, Fry AM, Garten RJ, et al: Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008-2010. J Infect Dis 2011;203:13-17
8. Pizzorno A, Bouhy X, Abed Y, et al: Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011;203:25-31
9. Luke TC, Casadevall A, Watowich SJ, et al: Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38(Suppl 4): e66-e73
10. Treanor JJ: Avian influenza: exploring all the avenues. Ann Intern Med 2006;145:631-632
11. Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007;357:1450-1451
12. Hung IF, To KK, Lee CK, et al: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52:447-456
13. Rockman S, Maher D, Middleton D: The use of hyperimmune serum for severe influenza infections. Crit Care Med 2012;40:970-972
14. Govorkova EA, Ilyushina NA, Boltz DA, et al: Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007;51:1414-1424